Luye Pharma Group Ltd.

LYPHF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$4,937,145$3,238,973$2,323,740$2,438,252
Short-Term Investments$1,566,067$1,271,695$3,220,524$3,072,057
Receivables$4,300,696$2,587,657$1,783,686$1,765,096
Inventory$911,893$827,863$772,939$746,344
Other Curr. Assets$1,592,306$1,181,327$2,684,924$2,374,915
Total Curr. Assets$13,308,107$10,703,282$10,785,813$10,396,664
Property Plant & Equip (Net)$5,890,856$5,088,505$4,909,126$4,594,470
Goodwill$1,012,456$1,041,930$1,003,371$985,413
Intangibles$6,585,487$4,804,781$5,984,684$5,441,833
Long-Term Investments$926,338$696,739-$2,106,440-$2,489,862
Tax Assets$163,578$1,271,695$113,947$133,106
Other NC Assets$1,725,378$3,155,478$3,559,124$3,520,437
Total NC Assets$16,304,093$14,787,433$13,463,812$12,185,397
Other Assets$0$0$0$0
Total Assets$29,612,200$25,490,715$24,249,625$22,582,061
Liabilities
Payables$689,300$767,187$559,944$570,890
Short-Term Debt$7,585,074$5,195,754$6,839,788$5,263,216
Tax Payable$434,680$294,891$256,323$205,072
Deferred Revenue$0$0$0$0
Other Curr. Liab.$2,060,088$1,879,975$1,831,148$1,291,015
Total Curr. Liab.$10,769,142$8,137,807$9,487,203$7,330,193
LT Debt$2,735,980$3,228,193$2,264,731$4,227,577
Deferred Rev, NC$118,207$0$174,965$209,387
Deferred Tax Liab, NC$36,479$0$56,034$57,874
Other NC Liab.$198,722$596,221$1,455,969$1,910,388
Total NC Liab.$3,089,388$3,824,414$3,720,700$6,137,965
Other Liabilities$0$0$0$0
Cap. Leases$61,955$70,646$38,491$41,950
Total Liabilities$13,858,530$11,962,221$13,207,903$13,468,158
Equity
Pref Stock$0$0$0$0
Common Stock$486,107$486,107$456,953$455,835
Retained Earnings$0$7,380,544$6,667,268$6,061,829
AOCI$0$505,214$254,463$534,036
Other Equity$13,668,422$4,159,320$2,797,270$1,436,423
Total Equity$14,154,529$12,531,185$10,175,954$8,488,123
Supplemental Information
Minority Interest$1,599,141$997,309$865,768$625,780
Total Liab. & Tot. Equity$29,612,200$25,490,715$24,249,625$22,582,061
Net Debt$5,383,909$5,184,974$6,780,779$7,052,541